JP2025507852A - 中環状または大環状ベンジル置換複素環誘導体および関連の使用 - Google Patents

中環状または大環状ベンジル置換複素環誘導体および関連の使用 Download PDF

Info

Publication number
JP2025507852A
JP2025507852A JP2024551975A JP2024551975A JP2025507852A JP 2025507852 A JP2025507852 A JP 2025507852A JP 2024551975 A JP2024551975 A JP 2024551975A JP 2024551975 A JP2024551975 A JP 2024551975A JP 2025507852 A JP2025507852 A JP 2025507852A
Authority
JP
Japan
Prior art keywords
compound
alkyl
pharma
present disclosure
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507852A5 (https=
Inventor
グレゴリー アール． オット，
カール ギブソン，
ブルース レフカー，
ポール ハンフリーズ，
マシュー スペンディフ，
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2025507852A publication Critical patent/JP2025507852A/ja
Publication of JP2025507852A5 publication Critical patent/JP2025507852A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024551975A 2022-03-01 2023-03-01 中環状または大環状ベンジル置換複素環誘導体および関連の使用 Pending JP2025507852A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US63/315,438 2022-03-01
US202363439477P 2023-01-17 2023-01-17
US63/439,477 2023-01-17
PCT/US2023/014275 WO2023167925A1 (en) 2022-03-01 2023-03-01 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Publications (2)

Publication Number Publication Date
JP2025507852A true JP2025507852A (ja) 2025-03-21
JP2025507852A5 JP2025507852A5 (https=) 2026-03-10

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551975A Pending JP2025507852A (ja) 2022-03-01 2023-03-01 中環状または大環状ベンジル置換複素環誘導体および関連の使用

Country Status (12)

Country Link
US (2) US20250236629A1 (https=)
EP (1) EP4486748A1 (https=)
JP (1) JP2025507852A (https=)
KR (1) KR20240157067A (https=)
CN (1) CN119110802A (https=)
AU (1) AU2023228830A1 (https=)
CA (1) CA3245204A1 (https=)
CL (1) CL2024002576A1 (https=)
IL (1) IL315237A (https=)
MX (1) MX2024010608A (https=)
TW (1) TW202400606A (https=)
WO (1) WO2023167925A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Also Published As

Publication number Publication date
CN119110802A (zh) 2024-12-10
US20250289828A1 (en) 2025-09-18
CL2024002576A1 (es) 2025-01-10
TW202400606A (zh) 2024-01-01
US20250236629A1 (en) 2025-07-24
IL315237A (en) 2024-10-01
EP4486748A1 (en) 2025-01-08
WO2023167925A1 (en) 2023-09-07
CA3245204A1 (en) 2023-09-07
MX2024010608A (es) 2024-09-23
AU2023228830A1 (en) 2024-09-12
KR20240157067A (ko) 2024-10-31

Similar Documents

Publication Publication Date Title
US12503475B2 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
JP2025507852A (ja) 中環状または大環状ベンジル置換複素環誘導体および関連の使用
JP7443625B2 (ja) ビシクロヘプタンピロリジンオレキシン受容体アゴニスト
EP3891157A1 (en) 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
TW202003466A (zh) 人類整合素α４β７拮抗劑
JP7207634B2 (ja) Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
TW201734001A (zh) ＲＯＲ－γ調節劑
CN119156375A (zh) 双环杂环衍生物和相关用途
JP2024516633A (ja) オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物
TW202417432A (zh) 抗菌化合物
JP2025516719A (ja) Ｎｌｒｐ３を阻害するためのオキソインドリニルアミド誘導体およびその使用
CN114641466B (zh) 磺酰脲衍生物及其用途
WO2020249669A1 (en) Sulfonamide derivatives and uses thereof
EA052303B1 (ru) Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения
TW202537962A (zh) 抑制α-V β-1整合素
TW202530205A (zh) 經取代之芳基磺醯胺及其組合物及用途
HK40039990B (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260302